For part 3 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the favorable safety and efficacy profile of nipocalimab for generalized myasthenia gravis (gMG).
The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback